审查生物标志物开发的标准蓝图,以解决新兴的癌症早期检测技术
Ruth Etzioni1, Roman Gulati1, Christos Patriotis2
1Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Journal of the National Cancer Institute
|November 9, 2023
概括
针对癌症早期检测的新型液体活检检测需要严格的评估. 早期检测研究网络.
科学领域:
- 在瘤学瘤学.
- 生物标志物发现发现
- 翻译研究是翻译研究.
背景情况:
- 液体活检技术正在推进癌症的早期检测.
- 对这些新型测试的人口查证据仍在发展.
- 需要重新评估生物标志物评估的现有框架.
研究的目的:
- 审查早期检测研究网络的生物标志物发展阶段 (PBD).
- 讨论新的查生物标志物的加快评估所带来的挑战和好处.
- 探索使用计算建模来评估查影响.
主要方法:
- 早期检测研究网络生物标志物 (PBD) 开发阶段的审查.
- 在加速生物标志物评估中讨论危险和机遇.
- 探索用于查影响评估的计算疾病建模.
主要成果:
- PBD需要足够的灵敏度,有意义的阶段转移,以及对人口查的死亡率的好处.
- 正在考虑采用较短终点的加快试验设计.
- 对于PBD标准对加快评估的严格应用需要进一步确定.
结论:
- 严格评估新的早期检测生物标志物至关重要.
- 在生物标志物评估中,平衡速度与科学严谨性至关重要.
- 计算建模为评估查影响提供了一个潜在的工具.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


